Dr. Nathaniel Schuster recently completed a double-blind, placebo-controlled, crossover, randomized controlled trial of vaporized cannabis as a potential acute treatment of migraines. At the conclusion of the trial, 4 puffs of vaporized THC/CBD mix flower was efficacious for acute migraine treatment, showing impacts on 2 hour pain relief and freedom, as well as resolution of most bothersome symptom 2 hours after migraine attack. Dr. Schuster recently reported on his findings at the 2023 American Headache Society (AHS) Annual Meeting. CMCR assisted in his research by designing the mobile application used to collect user responses and guide them through the study procedures.